Phosphorylated sphingolipids ceramide-1-phosphate (C1P) and sphingosine-1-phosphate (S1P) have emerged as key regulators of cell growth, survival, migration and inflammation 1-5 . C1P produced by ceramide kinase is an activator of group IVA cytosolic phospholipase A 2 a (cPLA 2 a), the rate-limiting releaser of arachidonic acid used for pro-inflammatory eicosanoid production 3,6-9 , which contributes to disease pathogenesis in asthma or airway hyper-responsiveness, cancer, atherosclerosis and thrombosis. To modulate eicosanoid action and avoid the damaging effects of chronic inflammation, cells require efficient targeting, trafficking and presentation of C1P to specific cellular sites. Vesicular trafficking is likely 10 but non-vesicular mechanisms for C1P sensing, transfer and presentation remain unexplored 11,12 . Moreover, the molecular basis for selective recognition and binding among signalling lipids with phosphate headgroups, namely C1P, phosphatidic acid or their lyso-derivatives, remains unclear. Here, a ubiquitously expressed lipid transfer protein, human GLTPD1, named here CPTP, is shown to specifically transfer C1P between membranes. Crystal structures establish C1P binding through a novel surface-localized, phosphate headgroup recognition centre connected to an interior hydrophobic pocket that adaptively expands to ensheath differing-length lipid chains using a cleft-like gating mechanism. The two-layer, a-helically-dominated 'sandwich' topology identifies CPTP as the prototype for a new glycolipid transfer protein fold 13 subfamily. CPTP resides in the cell cytosol but associates with the trans-Golgi network, nucleus and plasma membrane. RNA interferenceinduced CPTP depletion elevates C1P steady-state levels and alters Golgi cisternae stack morphology. The resulting C1P decrease in plasma membranes and increase in the Golgi complex stimulates cPLA 2 a release of arachidonic acid, triggering pro-inflammatory eicosanoid generation.
(SM), phosphatidylcholine (PC), phosphatidic acid (PA) or ceramide (Cer) by GLTPD1 (Fig. 1b, c) . Slow-down of AV-C1P transfer by potential lipid ligands (nonfluorescent) showed no competition effect by S1P ( Fig. 1d and Supplementary Fig. 1e , f) and a transfer rate of ,4 C1P molecules per min per protein molecule at 37 uC. We have designated GLTPD1 as ceramide-1-phosphate transfer protein (CPTP).
The crystal structure of human CPTP and 16:0-C1P complex (1.9 Å , Supplementary Table 1 ) revealed a two-layered, all a-helical topology ( Fig. 1e -g) homologous with the GLTP fold 13 . aN, a1 and a2 form one layer, a4, a5 and a8 form another layer, and a3, a6 and a7 localize along the periphery of the two-layer core. A positively-charged surface cavity for anchoring the lipid headgroup ( Fig. 1h ) extends through a *These authors contributed equally to this work. 1 Structural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA. 2 Hormel Institute, University of Minnesota, Austin, Minnesota 55912, USA. 3 Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia 23298, USA. 4 Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. 5 Structural Biology Unit, CIC bioGUNE, Technology Park of Bizkaia, 48160 Derio-Bilbao, Spain. 6 Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, Virginia 23249; Massey Cancer Center, Richmond, Virginia 23298, USA. (Fig. 2b) . The positive-charge of this site also is enhanced by R97 (a3-4 loop) which hydrogen bonds to the O2 atom of phosphate through water-bridging. R97 is almost fully active when mutated to Leu (R97L), but mutation to acidic Glu (R97E) reduces C1P transfer to ,55%, supporting its role for attracting the lipid phosphate headgroup. Cation-pi interaction between R113 (a4helix) and Y149 (a5-6 loop) provides stabilizing underpinning for the site ( Supplementary Fig. 2c ), as the R113 mutation (R113L) strongly diminishes activity. Mutants Y149A, R113E and R113L show poor C1P transfer, as expected by conformational destabilization (Fig. 2b ). All key residues of the phosphate recognition site appear to be conserved in eukaryotes ( Supplementary Fig. 2a ). The hydrophobic pocket is lined by ,25 nonpolar residues, mainly Phe, Leu, Val and Ile ( Fig. 2c and Supplementary Fig. 2b ) that prevent water entry while ensheathing the ceramide aliphatic chains. Mutation of L43, L118 or L146 to positively-charged Arg, or V57 or V158 to high polarity Asn compromises hydrophobic pocket functionality and strongly diminishes C1P transfer ( Fig. 2d ). More conservative mutation (for example, W117A) only moderately reduces C1P transfer, whereas F42A near the pocket bottom stimulates C1P transfer. Mutation near the entry portal (I53N) or in the flexible a1-2 loop (F50R) is well tolerated (75-80% active) ( Fig. 2d ). Ceramide entry is oriented by hydrogen bonding of the lipid amide oxygen and nitrogen with H150 and D56, respectively. Hydrogen bond disruption between lipid amide nitrogen and D56 (D56V) moderately slows C1P transfer, but H150 mutation (H150L) abolishes activity. Superpositioning of apoand 16:0-C1P-CPTP structures (root mean squared deviation (r.m.s.d.) 1.4 Å ) shows K60, R106 and R110 nearly identically positioned in the positively-charged surface cavities. Yet, large conformational differences exist for I53, W36, W119 and F52 ( Fig. 2e ) due to closer packing of certain a-helices in apo-CPTP ( Supplementary Fig. 2d , e). Many Leu and Phe are repositioned, reducing the solvent accessible volume (40 Å 3 ) (Supplementary Table 4 ) and effectively collapsing the hydrophobic pocket ( In sphingosine-out mode ( Fig. 2j and Supplementary Fig. 3d ), a bend in sphingosine at C6 is stabilized by hydrophobic interactions with V153, V154 and the D56 Cb atom, enabling outward projection. Sphingosine cross-bridging interactions with F50, I149, A157 and V153 of neighbouring, symmetry-related CPTP stabilize further (Supplementary Fig. 4b ). Solvent accessible pocket volumes reflect the altered sphingosine location, that is, 261 Å 3 for sphingosine-out versus 329 Å 3 for sphingosine-in (Supplementary Table 4 ). In 18:1-C1P-CPTP complex ( Fig. 3a, b ), the cis-double bond kink in the acyl chain increases separation from the sphingosine chain, maximally expanding the pocket (stereo view; Supplementary Fig. 4c, d ) although leaving the overall chain length in the pocket similar to 16:0-C1P. Accordingly, the solvent accessible volume of the hydrophobic pocket of 18:1-C1P-CPTP is larger (387 Å 3 ) ( Supplementary Table 4 ) than in 16:0-C1P-CPTP where slightly closer packing by the saturated acyl chain decreases the solvent accessible volume (364 Å 3 ). Shortening the acyl chain length reduces solvent accessible pocket volumes to 104 Å 3 for 8:0 and 263 Å 3 for 2:0 (Supplementary Table 4 ). Structures for 2:0-C1P-CPTP (sphingosine-in) and 8:0-C1P-CPTP (sphingosine-out) are detailed in Supplementary Figs 3a, b and 4e, f and Supplementary Discussion.
The functional consequences of CPTP hydrophobic pocket structural adaptability become clear upon transfer analyses. Pocket expansion accommodates ceramide aliphatic chains in 'molecular ruler'-like fashion with CPTP adaptability limits optimized for 16:0-or 18:1-C1P species which are particularly effective competitors at slowing the AV-C1P transfer rate ( Fig. 3g ), consistent with maximal pocket expansion and optimal fit (Supplementary Table 4 ). It is noteworthy that C1P containing long lignoceryl (24:0) acyl chains are not very effective competitors, suggesting poor accommodation in the hydrophobic pocket Table 1 ). Phosphatidic acid occupies the same binding site and its phosphate group interacts with the same positively charged residues as C1P ( Supplementary Fig. 5b-d ). Yet, K60 hydrogen bonding is single rather than bifurcated, and the lack of the acyl-amide moiety results in no hydrogen bonding with D56, distorting the position of the phosphate headgroup and both lipid chains and loosening phosphatidic acid binding. The distorted interaction mitigates phosphatidic acid transfer by CPTP ( Supplementary  Fig. 5e-h and Supplementary Discussion) .
CPTP architecture not only represents a new motif for specific binding of phosphosphingolipids, but is previously unknown for any phosphate-modified biomolecule [15] [16] [17] . In CPTP, the fixed cationic residues of the phosphate recognition site undergo minimal conformational change upon C1P binding. B-factor distribution analyses show the regions between a1-a2 and a5-a6 are most flexible (Supplementary Fig. 6a, b) , consistent with a cleft-like gating mechanism facilitating ceramide chain entry or exit. The conserved lipid orientation in the pocket, with the nonpolar acyl chain always inside regardless of sphingosine being in or out, supports a concerted mechanism of action in which the acyl chain enters first and leaves last during membrane interaction ( Supplementary Fig. 6c, d and Supplementary Discussion) .
The conformational adaptability of the inherently flexible, singlecavity, hydrophobic pocket of CPTP contrasts with lipid cavities in fatty acid binding proteins which use b-barrels/b-cups to generate a large, solvent-filled binding site that remains conformationally fixed whether or not occupied by fatty acid 18 . A single, fixed, lipid binding cavity also is characteristic of START lipid binding domains in PC transfer protein 19 and CERT (ref. 20) , which uses an a/b fold built around an incomplete U-shaped b-barrel to bind ceramide 21 (Supplementary Fig. 7 and Supplementary Discussion).
In the human genome, the differing origins of CPTP and GLTP are clear. CPTP (214 amino acids) is encoded by a three-exon transcript originating from GLTPD1 on chromosome 1 (locus 1p36.33). GLTP (209 amino acids) is encoded by a five-exon transcript originating from GLTP on chromosome 12 (locus 12q24.11) 22 . The shared folding topology encoded by GLTPD1 and GLTP, despite only limited sequence homology ( Supplementary Fig. 8a-e ) and different lipid specificity, provides a striking example of evolutionary convergence and emphasizes the structural premium placed by eukaryotes on conservation of this fold [23] [24] [25] . The related architectures of CPTP and GLTP, but with naturally evolved and remarkably different lipid headgroup specificity (Supplementary Discussion), suggest that the term 'sphingolipid transfer protein (SLTP) superfamily' might better reflect the existence of the two major subfamilies: CPTP, with selectivity for ceramide-linked phosphates; and GLTP, with selectivity for ceramide-linked sugars.
In cells, CPTP tracked by monospecific antibody or fluorescent epitope tag enhanced green fluorescent protein (EGFP) is localized in the cytosol but also associates with perinuclear membranes (for example, Golgi/trans-Golgi network (TGN)/endosomes), nuclei and plasma membranes (Fig. 3i-n and Supplementary Fig. 9 ). No localization to mitochondria, lysosomes or the endoplasmic reticulum is detected. CPTP co-localization with TGN-46 verified interaction with the TGN, a site where ceramide kinase (CERK) generates C1P (refs 3, 26-28) and led us to propose a C1P regulatory/sensing role for CPTP during CERK-mediated metabolic/signalling events. Short interfering 
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RNA (siRNA)-induced CPTP downregulation (,90%; Supplementary  Fig. 10a ) elevated both 16:0-C1P and 24:1-C1P (,4-fold) ( Fig. 4a ) and fragmented the Golgi cisternal stacks ( Supplementary Fig. 11 ).
RNAi-induced C1P changes were partially rescued with moderatelyactive R110L and K60N, but not with inactive K60A and R106L mutants (Fig. 4b) . CPTP overexpression in the absence of RNAi decreased 16:0-C1P and 24:1-C1P. K60A or R106L overexpression had the opposite effect ( Supplementary Fig. 12 ) and fragmented the Golgi cisternal stacks (not shown) consistent with a dominant-negative effect. CPTP depletion measurably decreased sphingosine and S1P ( Supplementary Fig. 10b, c) , 14:0-, 22:0-, 24:1-and 24:0-sphingomyelin, 16:0-monohexosylceramide, and 24:0-Cer, but modestly increased 24:1-Cer ( Supplementary Fig. 10d-f and Supplementary Discussion). Subcellular fractionation showed increased 16:0-C1P levels in 'heavy' membranes (TGN/endosome-enriched) and nuclear fractions, and decreased levels in plasma membranes without affecting levels in 'light' membranes (cis-Golgi/endoplasmic reticulum (ER)-enriched). These CPTP-depletion induced effects were rescued by ectopic wild-type CPTP expression ( Fig. 4g, Supplementary Fig. 13c and Supplementary Discussion).
Because CERK-generated C1P induces Group IVA cPLA 2 a activity which releases arachidonic acid used to produce pro-inflammatory eicosanoids 26, 27 , CPTP involvement was assessed. In siRNA-induced CPTP-depleted cells, arachidonic acid increased (Fig. 4c ) consistent with C1P accumulation at the Golgi/TGN that activates cPLA 2 a (ref. 26 ). Also elevated were major arachidonic acid metabolites generated by cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP) pathways, that is, PGE2, PGF2a, 6-keto-PGF1a (COX, Fig. 4d ); 5HETE, 8HETE, 12HETE (LOX, Fig. 4e ); 11,12 EET (CYP, Fig. 4f ). By contrast, arachidonic acid and eicosanoid levels decreased upon overexpression of wild-type CPTP but not the K60A or R106L mutant ( Supplementary Fig. 14) . Parallel siRNA-induced downregulation of CERK ( Supplementary Fig. 10 ), the only established producer of C1P in mammals, decreased 16:0-C1P (Fig. 4a ), arachidonic acid (Fig. 4c) , and eicosanoids ( Fig. 4d-f ) elevated by CPTP depletion. Figure 4h depicts a model showing how CPTP could regulate proinflammatory eicosanoid generation. In mammals, the only established pathway for C1P production is through phosphorylation of ceramide by CERK at the cytoplasmic surface of the TGN 3, 28 . CERK also contains nuclear localization/export signals and traffics to the plasma membrane by microtubule-driven vesicles in response to hyperosmotic shock 28 . To produce C1P, CERK uses ceramide delivered from its endoplasmic reticulum synthetic site to the Golgi by either CERT (ref. 27) or possibly by vesicular trafficking 10 . C1P elevation by CERK is known to activate soluble cPLA 2 a by enhancing translocation to the TGN 3,26 , where cPLA 2 a action releases arachidonic acid needed by eicosanoid producers such as COX-1 or COX-2. siRNA-induced CPTP depletion elevates C1P in the Golgi complex and nucleus, but lowers C1P plasma membrane levels. We propose that CPTP prevents excess C1P accumulation after production by CERK, thereby regulating cPLA 2 a action, CPTP mutants, but not inactive K60A and R106L CPTP mutants with siRNA targeted to endogenous the CPTP 39 UTR. c-f, Arachidonic acid (AA) and eicosanoids (COX, LOX and CYP pathways) secreted into media by siRNAtreated and control A549 cells (blue, siControl; red, siCPTP; green siCERK). Data for b and d-g represent averages of 6 experiments (2 procedures) by Student's t-test (*P , 0.05, **P , 0.01; NS, not significant). 6keto-PGF1a, the primary prostacyclin metabolite, is nearly unaffected by siCPTP or siCERK suggesting existence of an arachidonic acid pool derived independently of C1Pactivated cPLA 2 a. g, Changes in C1P levels at various subcellular locations by CPTP-siRNA. Shown on the x axis are the C1P species containing sphingosine base chains (d 18:1 ) and either 16:0 or 24:1 acyl chains. PM, plasma membranes; LM, light membranes (ER/cis-Golgi enriched); HM, heavy membranes (trans-Golgi/endosome/mitochondria enriched); NM, nuclear membranes. Data represent the mean 6 s.d. of three independent experiments. h, Model for CPTP regulation of eicosanoid production. C1P is synthesized by ceramide kinase (CERK) which concentrates in the trans-Golgi network vicinity via its pleckstrin homology (PH) domain during stimulation. To produce C1P, CERK uses ceramide transported from the ER by ceramide transfer protein (CERT) which also contains a targeting PH domain. After synthesis, C1P is transported to subcellular destinations by CPTP and possibly by vesicular trafficking. RNAi knockdown of CPTP (shown by the red x) leads to accumulation and elevation of C1P at the Golgi complex, a condition that activates soluble cytosolic phospholipase A 2 a (cPLA 2 a), releasing arachidonic acid needed for generation of downstream, pro-inflammatory eicosanoids. CPTP overexpression has the opposite effect on lipid levels. cPLA 2 a activation occurs by translocation from the cytoplasm and/or cis-Golgi (red arrows) through enhanced anchoring to C1P generated by CERK in the TGN. COX-1 and inducible COX-2 which use arachidonic acid to produce pro-inflammatory prostaglandins, also concentrate in the TGN vicinity during stimulation. For clarity, other eicosanoid generator pathways, that is, LOX (for example, cytoplasmic 5-lipoxygenase) and CYP (ER-associated cytochrome P450), are not depicted. Also not depicted is Golgi cisternal stack fragmentation induced by 24 h of CPTP RNAi.
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diminishing arachidonic acid release and downstream generation of pro-inflammatory eicosanoids. One destination for CPTP cargo is the plasma membrane. Models involving CPTP in catabolic C1P generation by sphingomyelinase D are less plausible because mammalian cells lack this enzyme 3 ( Supplementary Discussion) .
Previously, the only identified mechanism for regulating CERKmediated production of C1P was by control of ceramide availability through ceramide transfer protein 27 . It is noteworthy that siRNAinduced CPTP depletion yields the highest increase in endogenous C1P reported to date, mostly as 16:0-C1P, and dramatically alters Golgi cisternal stack morphology indicating CPTP-mediated transport is essential for maintaining proper Golgi organization by safeguarding localized C1P levels. The ensuing stimulation in eicosanoid production triggered by elevated C1P in the Golgi complex potentially implicates CPTP in, as of yet unidentified, disease states associated with inflammation.
METHODS SUMMARY
CPTP was cloned and expressed in BL21 (DE3) Star cells using pET-SUMO vector. Lipid intervesicular transfer assays were performed by Förster resonance energy transfer. X-ray diffraction data were collected on crystals of mouse apo-CPTP and of human CPTP with bound C1P containing acyl chains of differing length, for example, 2:0, 8:0, 12:0, 16:0 and 18:1, as well as di-12:0 PA. For phasing, singlewavelength anomalous dispersion data were collected for Se-Met-labelled, 8:0-C1P-CPTP crystal complex at Se peak wavelength (Supplementary Table 2 ) enabling other structures to be solved by molecular replacement. Data collection, processing, structure solution and refinement are described in the Methods. Protein docking with membranes was performed using the Orientation of Proteins with Membranes modelling. Epifluorescence microscopy images of fixed BSC-1 cells were captured by labelling with anti-CPTP antibody and anti-TGN-46, anti-GM130, anti-p230, anti-Rab5 or anti-Rab9 followed by secondary antibodies coupled to Alexa Fluor 488, Alexa Fluor 594, or Alexa Fluor 660 and counterstaining with DAPI (49,6diamidino-2-phenylindole). Reverse transcription PCR and quantitative PCR were used to evaluate endogenous CPTP mRNA tissue levels and siRNA-downregulated CPTP and CERK transcript levels. Sphingolipids were analysed by electrospray ionization tandem mass spectrometry (ESI-MS/MS) after separation by HPLC. Eicosanoids were analysed as detailed by the Lipid Maps Consortium.
